Literature DB >> 27260686

Diagnostic and prognostic significance of serum apolipoprotein C-I in triple-negative breast cancer based on mass spectrometry.

Dongjian Song1,2, Lifang Yue3, Junjie Zhang1, Shanshan Ma4, Wei Zhao1, Fei Guo1, Yingzhong Fan1, Heying Yang1, Qiuliang Liu1, Da Zhang1, Ziqiang Xia1, Pan Qin1, Jia Jia1, Ming Yue1, Jiekai Yu5, Shu Zheng5, Fuquan Yang6, Jiaxiang Wang1.   

Abstract

Women with triple-negative breast cancer (TNBC) have poor prognosis because of the aggressive nature of the tumor, delayed diagnosis and non-specific symptoms in the early stages. Identification of novel specific TNBC serum biomarkers for screening and therapeutic purposes therefore remains an urgent clinical requirement.We obtained serum samples from a total of 380 recruited individuals split into mining and testing sets, with the aim of screening for reliable protein biomarkers from TNBC and non-TNBC (NTNBC) sera. Samples were assessed using mass spectrometry, followed by receiver operating characteristic (ROC), survival and hazard function curve as well as multivariate Cox regression analyses to ascertain the potential of the protein constituents as diagnostic and prognostic biomarkers for TNBC.We identified upregulated apolipoprotein C-I (apoC-I) with a validated positive effect on TNBC tumorigenesis, with confirmation in an independent test set and minimization of systematic bias by pre-analytical parameters. The apoC-I protein had superior diagnostic ability in distinguishing between TNBC and NTNBC cases. Moreover, the protein presented a more robust potential prognostic factor for TNBC than NTNBC. The apoC-I protein identified in this study presents an effective novel diagnostic and prognostic biomarker for TNBC, indicating that measurement of the peak intensity at 7785 Da in serum samples could facilitate improved early detection and estimation of postoperative survival prognosis for TNBC.

Entities:  

Keywords:  Apolipoprotein C-I; biomarker; breast cancer; diagnosis; mass spectrometry; prognosis; serum

Mesh:

Substances:

Year:  2016        PMID: 27260686      PMCID: PMC4990397          DOI: 10.1080/15384047.2016.1156262

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  73 in total

Review 1.  Triple-negative breast cancer.

Authors:  William D Foulkes; Ian E Smith; Jorge S Reis-Filho
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

2.  Detection of two distinct forms of apoC-I in great apes.

Authors:  Donald L Puppione; Christopher M Ryan; Sara Bassilian; Puneet Souda; Xinshu Xiao; Oliver A Ryder; Julian P Whitelegge
Journal:  Comp Biochem Physiol Part D Genomics Proteomics       Date:  2010-03       Impact factor: 2.674

3.  Bring on the biomarkers.

Authors:  George Poste
Journal:  Nature       Date:  2011-01-13       Impact factor: 49.962

4.  Comprehensive plasma profiling for the characterization of graft-versus-host disease biomarkers.

Authors:  Muriel De Bock; Yves Beguin; Pierre Leprince; Evelyne Willems; Frédéric Baron; Céline Deroyer; Laurence Seidel; Etienne Cavalier; Dominique de Seny; Michel Malaise; André Gothot; Marie-Paule Merville; Marianne Fillet
Journal:  Talanta       Date:  2014-03-18       Impact factor: 6.057

5.  Breast cancer in a multi-ethnic Asian setting: results from the Singapore-Malaysia hospital-based breast cancer registry.

Authors:  Nirmala Bhoo Pathy; Cheng Har Yip; Nur Aishah Taib; Mikael Hartman; Nakul Saxena; Philip Iau; Awang M Bulgiba; Soo Chin Lee; Siew Eng Lim; John E L Wong; Helena M Verkooijen
Journal:  Breast       Date:  2011-02-12       Impact factor: 4.380

6.  Evaluating the effectiveness of using standard mammogram form to predict breast cancer risk: case-control study.

Authors:  Jane Ding; Ruth Warren; Iqbal Warsi; Nick Day; Deborah Thompson; Michael Brady; Christopher Tromans; Ralph Highnam; Douglas Easton
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-05       Impact factor: 4.254

7.  Analysis of the differences of serum protein mass spectrometry in patients with triple negative breast cancer and non-triple negative breast cancer.

Authors:  Ai-Na Liu; Ping Sun; Jian-Nan Liu; Cai-Yan Yu; Hua-Jun Qu; Ai-Hong Jiao; Liang-Ming Zhang
Journal:  Tumour Biol       Date:  2014-06-29

8.  The dyslipidemia-associated SNP on the APOA1/C3/A5 gene cluster predicts post-surgery poor outcome in Taiwanese breast cancer patients: a 10-year follow-up study.

Authors:  Mei-Chi Hsu; Kuo-Ting Lee; Wei-Chiang Hsiao; Chih-Hsing Wu; Hung-Yu Sun; I-Ling Lin; Kung-Chia Young
Journal:  BMC Cancer       Date:  2013-07-05       Impact factor: 4.430

9.  Modeling of hypo/hyperglycemia and their impact on breast cancer progression related molecules.

Authors:  Sirin A I Adham; Hasina Al Rawahi; Sumaya Habib; Mansour S Al Moundhri; Alicia Viloria-Petit; Brenda L Coomber
Journal:  PLoS One       Date:  2014-11-17       Impact factor: 3.240

10.  Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer.

Authors:  Liping Chung; Katrina Moore; Leo Phillips; Frances M Boyle; Deborah J Marsh; Robert C Baxter
Journal:  Breast Cancer Res       Date:  2014-06-16       Impact factor: 6.466

View more
  11 in total

1.  The effects and possible mechanism of action of apolipoprotein M on the growth of breast cancer cells.

Authors:  Ying Zhou; Shuang Yao; Miaomei Yu; Jiang Wei; Qi Fang; Ning Xu; Guanghua Luo
Journal:  Mol Biol Rep       Date:  2021-11-13       Impact factor: 2.316

2.  A key genomic subtype associated with lymphovascular invasion in invasive breast cancer.

Authors:  Sasagu Kurozumi; Chitra Joseph; Sultan Sonbul; Sami Alsaeed; Yousif Kariri; Abrar Aljohani; Sara Raafat; Mansour Alsaleem; Angela Ogden; Simon J Johnston; Mohammed A Aleskandarany; Takaaki Fujii; Ken Shirabe; Carlos Caldas; Ibraheem Ashankyty; Leslie Dalton; Ian O Ellis; Christine Desmedt; Andrew R Green; Nigel P Mongan; Emad A Rakha
Journal:  Br J Cancer       Date:  2019-05-22       Impact factor: 7.640

Review 3.  Apolipoproteins and cancer.

Authors:  Liwen Ren; Jie Yi; Wan Li; Xiangjin Zheng; Jinyi Liu; Jinhua Wang; Guanhua Du
Journal:  Cancer Med       Date:  2019-10-01       Impact factor: 4.452

Review 4.  Apolipoprotein C1: Its Pleiotropic Effects in Lipid Metabolism and Beyond.

Authors:  Elena V Fuior; Anca V Gafencu
Journal:  Int J Mol Sci       Date:  2019-11-26       Impact factor: 5.923

Review 5.  Apolipoproteins, as the carrier proteins for lipids, are involved in the development of breast cancer.

Authors:  Y Zhou; G Luo
Journal:  Clin Transl Oncol       Date:  2020-04-18       Impact factor: 3.405

Review 6.  Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer.

Authors:  Hsing-Ju Wu; Pei-Yi Chu
Journal:  Int J Mol Sci       Date:  2021-01-10       Impact factor: 5.923

Review 7.  Triple Negative Breast Cancer: A Review of Present and Future Diagnostic Modalities.

Authors:  Sylvia Annabel Dass; Kim Liu Tan; Rehasri Selva Rajan; Noor Fatmawati Mokhtar; Elis Rosliza Mohd Adzmi; Wan Faiziah Wan Abdul Rahman; Tengku Ahmad Damitri Al-Astani Tengku Din; Venugopal Balakrishnan
Journal:  Medicina (Kaunas)       Date:  2021-01-12       Impact factor: 2.430

Review 8.  Breast Cancer; Discovery of Novel Diagnostic Biomarkers, Drug Resistance, and Therapeutic Implications.

Authors:  Samia Afzal; Muhammad Hassan; Safi Ullah; Hazrat Abbas; Farah Tawakkal; Mohsin Ahmad Khan
Journal:  Front Mol Biosci       Date:  2022-02-21

9.  Circulating HDL and Non-HDL Associated Apolipoproteins and Breast Cancer Severity.

Authors:  Christine Bobin-Dubigeon; Hassan Nazih; Valentin Blanchard; Mikaël Croyal; Jean-Marie Bard
Journal:  J Clin Med       Date:  2022-02-28       Impact factor: 4.241

Review 10.  Lipoproteins and cancer: The role of HDL-C, LDL-C, and cholesterol-lowering drugs.

Authors:  Kush K Patel; Khosrow Kashfi
Journal:  Biochem Pharmacol       Date:  2021-06-12       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.